Helen Tomkinson

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model

Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov et al. · Journal for ImmunoTherapy of Cancer · 2018 · 111 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies

Helen Tomkinson, John Kemp, Stuart Oliver et al. · BMC Clinical Pharmacology · 2011 · 38 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

Shringi Sharma, Xavier Pépin, Lianqing Zheng et al. · Clinical Pharmacology in Drug Development · 2022 · 26 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

Patricia LoRusso, Jeffrey R. Infante, Kevin B. Kim et al. · BMC Cancer · 2017 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure

Weifeng Tang, Helen Tomkinson, Eric Masson · Clinical Pharmacology in Drug Development · 2017 · 19 citations

Medicine, Pharmacokinetics, Pharmacology +13